Using a Smart Ring to Track Heart Rate Changes in Rheumatoid Arthritis
Studies whether heart rate variability from a wearable ring relates to rheumatoid arthritis activity.
Plain-language title generated from the registry record
Registry title: HRV Variation in Rheumatoid Arthritis
Key facts
- Where
- Orlando, United StatesSee the site
Where in United States
- University of Central FloridaOrlando, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Central Florida
- Trial code
- NCT07878975
- Record updated
- 16 October 2026
- Original description
The goal of this observational study is to determine the association between continuous Heart Rate Variability (HRV) measured by the Oura ring and Rheumatoid Arthritis (RA) disease activity.Read full original descriptionShow less
Heart Rate Variability as a Continuous Digital Biomarker for Flare Activity Monitoring and Flare Resolution in Rheumatoid Arthritis: A Pilot Study Using the Oura Ring
The goal of this observational study is to determine the association between continuous Heart Rate Variability (HRV) measured by the Oura ring and Rheumatoid Arthritis (RA) disease activity.
Inclusion: Diagnosis of RA meeting 2010 ACR/EULAR classification criteria; Seropositive or seronegative RA eligible; Any baseline disease activity (remission/low/moderate/high) to minimize selection bias; Owns a compatible smartphone (iOS/Android) and is willing/able to use the Oura app; Willing to wear Oura Ring during sleep throughout study participation (target adherence ≥5 valid nights/week); Willing to complete weekly remote assessments and attend baseline and three monthly routine follow-up visits; Able to read and write English language; Able to provide written informed consent.
Exclusion: Atrial fibrillation or other clinically significant arrhythmias expected to invalidate HRV interpretation; Recent major cardiovascular event within 6 months (e.g., myocardial infarction) or uncontrolled heart failure (NYHA class III-IV), per investigator judgment; Implanted pacemaker/defibrillator where HRV measurements are unreliable; Severe autonomic dysfunction likely to interfere with HRV interpretation (e.g., advanced diabetic autonomic neuropathy), per investigator judgment; Current use of beta-blockers (excluded due to known autonomic/HRV effects); Pregnancy or planned pregnancy during the study period; Inability to wear the ring reliably (e.g., occupational restrictions or hand deformity preventing wear); Participation in another interventional clinical trial likely to confound outcomes.